460 related articles for article (PubMed ID: 27664113)
21. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future.
Nathan DI; Feld J; El Jamal SM; Mascarenhas J; Tremblay D
Leuk Res; 2022 Apr; 115():106820. PubMed ID: 35279478
[TBL] [Abstract][Full Text] [Related]
22. Clinical analysis and literature review of a case with the myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
Long B; Shi H; Zhu C
Hematology; 2020 Dec; 25(1):283-285. PubMed ID: 32657243
[No Abstract] [Full Text] [Related]
23. Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Palomo L; Meggendorfer M; Hutter S; Twardziok S; Ademà V; Fuhrmann I; Fuster-Tormo F; Xicoy B; Zamora L; Acha P; Kerr CM; Kern W; Maciejewski JP; Solé F; Haferlach C; Haferlach T
Blood; 2020 Oct; 136(16):1851-1862. PubMed ID: 32573691
[TBL] [Abstract][Full Text] [Related]
24. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM; Tefferi A
Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
[TBL] [Abstract][Full Text] [Related]
25. I walk the other line: myelodysplastic/myeloproliferative neoplasm overlap syndromes.
Gerds AT
Curr Hematol Malig Rep; 2014 Dec; 9(4):400-6. PubMed ID: 25195196
[TBL] [Abstract][Full Text] [Related]
26. Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review.
Fontana D; Elli EM; Pagni F; Piazza R
Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370785
[TBL] [Abstract][Full Text] [Related]
27. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
[TBL] [Abstract][Full Text] [Related]
28. Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T): 2017 update on diagnosis, risk-stratification, and management.
Patnaik MM; Tefferi A
Am J Hematol; 2017 Mar; 92(3):297-310. PubMed ID: 28188970
[TBL] [Abstract][Full Text] [Related]
29. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
Shallis RM; Zeidan AM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101132. PubMed ID: 32460977
[TBL] [Abstract][Full Text] [Related]
30. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
[TBL] [Abstract][Full Text] [Related]
31. Peculiarities in the Diagnosis Approach of MDS /MPN-U Patients.
Triantafyllidis I; Ciobanu A; Stanca O; Draghici C; Angelescu S; Tapelea E
Maedica (Bucur); 2012 Jun; 7(2):173-6. PubMed ID: 23401728
[TBL] [Abstract][Full Text] [Related]
32. Guest Editorial: Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspects.
Harada H
Int J Hematol; 2017 Jun; 105(6):709-710. PubMed ID: 28447249
[No Abstract] [Full Text] [Related]
33. Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist.
Li P; Shahmarvand N; Lynch D; Gotlib JR; Merker JD; Zehnder JL; George TI; Ohgami RS
Int J Lab Hematol; 2019 Jun; 41(3):345-352. PubMed ID: 30811101
[TBL] [Abstract][Full Text] [Related]
34.
Linder K; Iragavarapu C; Liu D
Biomark Res; 2017; 5():33. PubMed ID: 29225884
[TBL] [Abstract][Full Text] [Related]
35. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features.
Orazi A; Germing U
Leukemia; 2008 Jul; 22(7):1308-19. PubMed ID: 18480833
[TBL] [Abstract][Full Text] [Related]
36. Myelodysplastic and myeloproliferative neoplasms: updates on the overlap syndromes.
Thota S; Gerds AT
Leuk Lymphoma; 2018 Apr; 59(4):803-812. PubMed ID: 28771058
[TBL] [Abstract][Full Text] [Related]
37. Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms.
Gerke MB; Christodoulou I; Karantanos T
Cancers (Basel); 2023 Jul; 15(15):. PubMed ID: 37568631
[TBL] [Abstract][Full Text] [Related]
38. Myelodysplastic/myeloproliferative neoplasms.
Cazzola M; Malcovati L; Invernizzi R
Hematology Am Soc Hematol Educ Program; 2011; 2011():264-72. PubMed ID: 22160044
[TBL] [Abstract][Full Text] [Related]
39. JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia.
Jekarl DW; Han SB; Kim M; Lim J; Oh EJ; Kim Y; Kim HJ; Min WS; Han K
Korean J Hematol; 2010 Mar; 45(1):46-50. PubMed ID: 21120162
[TBL] [Abstract][Full Text] [Related]
40. Refractory anemia with ring sideroblasts and RARS with thrombocytosis.
Patnaik MM; Tefferi A
Am J Hematol; 2015 Jun; 90(6):549-59. PubMed ID: 25899435
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]